



**Silva Pharmaceuticals  
Limited**

**Utilization of IPO Fund Proceeds**

**For the month ended 31 December 2025**

**AUDITORS' REPORT**  
*on*  
**Utilization of IPO Proceeds**

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of Silva Pharmaceuticals Limited for the month ended 31<sup>st</sup> December 2025 as per required by Bangladesh Securities and Exchange Commission (BSEC) under Section 2CC of the Securities and Exchange Ordinance 1969.

**Management's Responsibility for the IPO proceeds Utilization**

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 2020, Condition laid down in clause 2, 3, 5 & 6 of PART-C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June 2018 and other applicable laws and regulations.

**Auditor's Responsibility**

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 2020, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Opinion**

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, prepared in accordance with Bangladesh Securities and Exchange Commission Rules 2020 and Condition laid down in clause 2, 3, 5 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations, gives a true and fair view of the statement for the month 31 December 2025.

**As per TOR, we draw attention to the following matter:**


1. During the month of December 2025, no expenses has been incurred in respect of Civil Construction. However, the company has utilized accumulative amount of Tk. 60,532,650 up to 31 December 2025 which was 104.26% of the amount specified in the prospectus and thereafter revised utilization plan for the purpose of Civil Construction. As such, approval was a pre-requisite from the respected shareholders and concerned regulatory authority for the excess utilized amount of Tk. 2,474,124.

2. During the month of December 2025, no expenses has been incurred in respect of purchase of new Machinery and Equipment's. However, the company has utilized accumulative amount of Tk. 94,317,362 which was 76.99% up to 31 December 2025 in respect of Purchase of Machinery and Equipment's.
3. The Company has utilized Tk. 99,000,000 which was 100% of the budgeted amount up to 31 December 2025 for the purpose of loan repayment as specified in the prospectus.
4. The Company has utilized Tk. 20,441,474 which was 100% of the budgeted amount up to 31 December 2025 for the purpose of IPO expenses as specified in the prospectus and thereafter revised utilization plan.

**We also state that:**

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus and thereafter revised utilization plan except the above said issues no.1 of the Company;
- b) IPO proceeds have been utilized in so far line with the conditions of the BSEC's consent letter for the IPO except the above said issues no. 1.
- c) The time frame for completion of the utilization of IPO proceeds was revised and will be completed within the time frame as specified in the resolution of 23<sup>rd</sup> Annual General Meeting (AGM).
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus and 18<sup>th</sup> AGM of the Company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

**Dhaka, Bangladesh**  
Dated: 06 January 2026

  
**Mesbah Uddin FCA**  
Partner  
ICAB Enroll No.: 1533  
FRC Enlistment No.: CA-001-177  
**Pinaki & Company**  
Chartered Accountants  
FRC Firm Enlistment No.: CAF-001-133

**Report on Utilization of IPO Proceeds  
For the Month of December 2025**

Name of the Company: Silva Pharmaceuticals Limited  
Amount (BDT) of capital raised through IPO: BDT 300,000,000  
Date of Close of Subscription: 05 August 2018  
Proceeds Receiving Date: 10 October 2018  
Last Date of Full Utilization of IPO Fund as per Prospectus: As stated in time line columns

S.L.	Purpose mentioned in the prospectus / 18th AGM	Time Line						Amount as per Prospectus	Amount as per 18th AGM	Status of Utilization				Remarks	
		As per Prospectus	As per 18th AGM	As per 19th AGM	As per 21st AGM	As per 22nd AGM	As per 23rd AGM			Total Utilized Amount	Utilized %	Excess Utilized amount	Excess-utilized %		Total unutilized amount
1	Civil Construction	09.04.2020	09.10.2020	31.12.2022	N/A	N/A	N/A	56,000,000	58,058,526	60,532,650	104.26	2,474,124	4.26	-	-
2	Machinery and Equipment	09.04.2020	09.10.2020	31.12.2022	31.12.2023	31.12.2024	31.12.2025	122,500,000	122,500,000	94,317,362	76.99	-	-	28,182,638	23.01
3	Repayment of Bank Borrowing at prospectus	09.01.2019	N/A	N/A	N/A	N/A	N/A	99,000,000	99,000,000	99,000,000	100.00	-	-	-	-
4	IPO Expenses	N/A	N/A	N/A	N/A	N/A	N/A	22,500,000	20,441,474	20,441,474	100.00	-	-	-	-
<b>Total</b>									<b>300,000,000</b>	<b>274,291,486</b>	<b>91.43</b>	<b>2,474,124</b>	<b>0.82</b>	<b>28,182,638</b>	<b>9.39</b>


**Notes:**

- Actual application was received almost 25.76 Times.
- IPO proceeds have been utilized for the purposes/heads as specified in the prospectus and in line with the condition of the Commission's consent letter.
- Interest on IPO Proceeds in BDT (from FDR & SND) - Net of Charges, Tax and Duties etc.
- Un-Utilized IPO Proceeds with interest income in BDT -

31,757,688
50,910,000

(Annexure-A)

  
Silvana Mirza  
Chairman

  
Mohammad Enayet Ullah  
DGM (Operations & CEO (c.c))

  
Md. Abul Kasem  
Chief Financial Officer

  
Md. Hossain  
Company Secretary

Mesbah Uddin FCA  
Partner  
ICAB Enroll. No.: 1533  
FRC Enlistment No.: CA-001-177  
Pinaki & Company  
Chartered Accountants  
FRC Firm Enlistment No.: CAF-001-133

Dhaka  
Dated : 06 January 2026

**Silva Pharmaceuticals Limited**

IPO Fund Reconciliation Statements

For the Month of December 2025

**Annexure-A**

Total unutilized amount (Machinery and Equipment)	28,182,638
<b>Add:</b> Interest on IPO Proceeds in BDT (from FDR & SND)-Net of Charges, Tax and Duties etc.	31,757,688
	<b>59,940,326</b>
<b>Less:</b> Excess utilized amount (Civil Construction)	2,474,124
<b>Less:</b> Transferred out of interest of unutilized IPO fund to CD account # 401211100007640	6,556,203
<b>Un-Utilized IPO Proceeds with interest income in BDT</b>	<b>50,910,000</b>

